Skip to Content

The Effectiveness of Risankizumab Following Guselkumab Failure in Moderate-to-Severe Psoriasis Patients

In this MEDtalk, Camille Hamm discusses a study that focused on interclass switching within the IL-23 class of biologics for the treatment of psoriasis. The study specifically looked at patients who had failed to respond to the drug guselkumab and were subsequently switched to risankizumab to evaluate the effectiveness of this switch.

Camille Hamm

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top